Novartis has unveiled plans to construct a new radioligand therapy (RLT) manufacturing facility in Denton, Texas. This project marks a significant milestone in the company’s 23-billion-dollar investment blitz in the United States, bringing its total domestic radiopharmaceutical production network to five sites. Construction is scheduled to begin this year, with the facility expected to be operational by 2028.
The 46,000-square-foot plant is designed to serve patients across the Southern U.S. and provide the necessary capacity as RLT treatments expand into earlier lines of therapy and additional cancer types. Currently, Novartis holds FDA approvals for two RLTs: Lutathera for neuroendocrine tumors and Pluvicto for prostate cancer.
The Texas facility joins a strategic network that includes sites in New Jersey, Indiana, California, and Florida. Beyond physical infrastructure, Novartis has been securing its supply chain through agreements with radioisotope suppliers to ensure a scalable stock of essential materials like Actinium-225. This expansion reflects the company’s commitment to advancing next-generation oncology care while reinforcing domestic manufacturing capabilities in response to evolving trade environments.